Tags: Drug.
Pertuzumab (also called 2C4 trade name Perjeta) is a monoclonal antibody marketed by Genentech for the treatment of HER2-positive breast cancer in combination with trastuzumab and docetaxel. The first of its class in a line of agents called HER dimerization inhibitors. By binding to HER2 it inhibits the dimerization of HER2 with other HER receptors which is hypothesized to result in slowed tumor growth.
